Literature DB >> 17825570

Selective angiotensin II AT(2) receptor agonists devoid of the imidazole ring system.

A M S Murugaiah1, Chalotta Wallinder, A K Mahalingam, Xiongyu Wu, Yiqian Wan, Bianca Plouffe, Milad Botros, Anders Karlén, Mathias Hallberg, Nicole Gallo-Payet, Mathias Alterman.   

Abstract

A versatile parallel synthetic method to obtain three series of non-cyclic analogues of the first drug-like selective angiotensin II AT(2) receptor agonist (1) has been developed. In analogy with the transformation of losartan to valsartan it was demonstrated that a non-cyclic moiety could be employed as an imidazole replacement to obtain AT(2) selective compounds. In all the three series, AT(2) receptor ligands with affinities in the lower nanomolar range were found. None of the analogues exhibited any affinity for the AT(1) receptor. Four compounds, 17, 22, 39 and 51, were examined in a neurite outgrowth cell assay. All four compounds were found to exert a high agonistic effect as deduced from their capacity to induce neurite elongation in neuronal cells, as does angiotensin II.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17825570     DOI: 10.1016/j.bmc.2007.07.026

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  9 in total

1.  Saralasin and Sarile Are AT2 Receptor Agonists.

Authors:  Marie-Odile Guimond; Mathias Hallberg; Nicole Gallo-Payet; Charlotta Wallinder
Journal:  ACS Med Chem Lett       Date:  2014-08-18       Impact factor: 4.345

2.  Interconversion of Functional Activity by Minor Structural Alterations in Nonpeptide AT2 Receptor Ligands.

Authors:  Charlotta Wallinder; Christian Sköld; Milad Botros; Marie-Odile Guimond; Mathias Hallberg; Nicole Gallo-Payet; Anders Karlén; Mathias Alterman
Journal:  ACS Med Chem Lett       Date:  2014-12-08       Impact factor: 4.345

Review 3.  The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target.

Authors:  U Muscha Steckelings; Robert E Widdop; Edward D Sturrock; Lizelle Lubbe; Tahir Hussain; Elena Kaschina; Thomas Unger; Anders Hallberg; Robert M Carey; Colin Sumners
Journal:  Pharmacol Rev       Date:  2022-10       Impact factor: 18.923

4.  Angiotensin II, a Neuropeptide at the Frontier between Endocrinology and Neuroscience: Is There a Link between the Angiotensin II Type 2 Receptor and Alzheimer's Disease?

Authors:  Nicole Gallo-Payet; Marie-Odile Guimond; Lyne Bilodeau; Charlotta Wallinder; Mathias Alterman; Anders Hallberg
Journal:  Front Endocrinol (Lausanne)       Date:  2011-08-26       Impact factor: 5.555

5.  A Series of Analogues to the AT2R Prototype Antagonist C38 Allow Fine Tuning of the Previously Reported Antagonist Binding Mode.

Authors:  Rebecka Isaksson; Jens Lindman; Johan Wannberg; Jessica Sallander; Maria Backlund; Dhaniel Baraldi; Robert Widdop; Mathias Hallberg; Johan Åqvist; Hugo Gutierrez de Teran; Johan Gising; Mats Larhed
Journal:  ChemistryOpen       Date:  2019-01-24       Impact factor: 2.911

6.  Evolution of Angiotensin Peptides and Peptidomimetics as Angiotensin II Receptor Type 2 (AT2) Receptor Agonists.

Authors:  Silvana Vasile; Anders Hallberg; Jessica Sallander; Mathias Hallberg; Johan Åqvist; Hugo Gutiérrez-de-Terán
Journal:  Biomolecules       Date:  2020-04-23

7.  Discovery of inhibitors of insulin-regulated aminopeptidase as cognitive enhancers.

Authors:  Hanna Andersson; Mathias Hallberg
Journal:  Int J Hypertens       Date:  2012-12-04       Impact factor: 2.420

8.  The Angiotensin II Type 2 Receptor in Brain Functions: An Update.

Authors:  Marie-Odile Guimond; Nicole Gallo-Payet
Journal:  Int J Hypertens       Date:  2012-12-25       Impact factor: 2.420

9.  N-Aryl Isoleucine Derivatives as Angiotensin II AT2 Receptor Ligands.

Authors:  Malte Behrends; Charlotta Wallinder; Anna Wieckowska; Marie-Odile Guimond; Anders Hallberg; Nicole Gallo-Payet; Mats Larhed
Journal:  ChemistryOpen       Date:  2014-03-13       Impact factor: 2.911

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.